Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$220.83 ▼ -0.89
(-0.40%)
MKT CAP: $88.52B • VOL: 8.44M
52W L $22 52W H $254
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$186
MEDIAN
$247
MEAN
$252
HIGH
$300
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MRNA TAPE
MRNA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $267.20 | $253.95 | 2025-02-14 | $200.96 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $278.25 | $260.58 | 2025-02-06 | $207.58 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $251.75 | $242.91 | 2025-01-29 | $212.00 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $225.25 | — | 2025-01-17 | $216.41 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $194.33 | $209.79 | 2025-01-09 | $196.54 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $262.79 | $229.66 | 2024-12-18 | $192.12 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $214.21 | $223.04 | 2024-12-04 | $205.37 | -4.3% | 48% | C |